cancer-gi-cancer-digestive-2018-scientifictracks

27 / 30

Page 72
Notes:
Journal of Gastrointestinal & Digestive System | ISSN: 2161-069X | Volume: 8
&
&
October 29-30, 2018 | San Francisco, USA
International Conference on
Gastrointestinal Cancer and Therapeutics
4th World Congress on
Digestive & Metabolic Diseases
26th Annual Congress on
Cancer Science and Targeted Therapies
Effect of the anti-cancer preparation NSC-631570 (Ukrain) in pancreatic carcinoma
Wassil Nowicky
Ukrainian Anti Cancer Institute, Austria
In a controlled randomised study by Beger et al. in the Ulm University Hospital, Germany, the therapy with NSC‐631570 and
gemcitabine doubled the survival rate in the patients with inoperable advanced pancreatic cancer. The longest survival was
19 months in the group treated with gemcitabine alone, 26 months in the combined group, and in the NSC‐631570 alone group
two patients were alive after 28 months. NSC‐631570 was well tolerated. The study authors consider further evaluation of
NSC‐631570 as justified whereas the quality of life of the patients improved. Patients were further observed after the conclusion
of the study and it was noted that UKRAIN was well tolerated and could be administered without problem to all patients.
UKRAIN brought about a significant increase in survival time in comparison to therapy with gemcitabine alone. Combination
therapy with gemcitabine and UKRAIN showed no advantage over monotherapy with UKRAIN. The longest survival in the
gemcitabine group was 19 months, 21 months in the gemcitabine+Ukrain group, and in the UKRAIN group a patient was
still alive after 28 months. The authors concluded: As a result of this study we highly recommend the treatment of patients
suffering from advanced pancreatic cancer with Ukrain. In 2007 the results of another clinical study by the same research team
were published. This time the efficacy of the adjuvant therapy with NSC‐631570 has been demonstrated in the patients with
advanced pancreatic cancer after surgery. The patients were treated with a combination of NSC‐631570 and gemcitabine. The
median survival was 33.8 months and the 5‐year survival rate was 23.3% which is clearly better than results reported in the
earlier studies without NSC‐631570, with the median survival of 20.1 months and the 5 years survival rate was 21%. Moreover,
NSC‐631570 at therapeutic dose range has only minimal adverse effects, improves the quality of life of patients and can be
administered also on outpatient basis. All these features distinguishes this drug favorable compared to the standard cytostatic
agents. Other researcher confirmed the efficacy of NSC‐631570 in pancreatic carcinoma, while the partial remission rate was
as high as 85.7% in one study. The longest survival in palliative therapy was more than six years.
Biography
Wassil Nowicky, Dipl. Ing., Dr techn., DDDr HC, Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished
his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplom Ingenieur” in 1960 which title
was nostrificated in Austria in 1975. He became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation
against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negatively charged than normal
cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Author of over 300 scientific articles
dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the
American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university
on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of the National
guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Wassil Nowicky, J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C8-085